Everything below concerns Peptidomimetic. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-22. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
== Research == While it is unclear whether PF-00446687 itself will be potent and effective enough to be developed for medical use, it has demonstrated that selectively targeting the MC4 subtype can produce similar aphrodisiac effects to older non-selective peptide-based melanocortin receptor agonists like melanotan II and bremelanotide, without the side effects caused by action at the other melanocortin receptor subtypes.
== Track listing == Intro – 0:39 Beyond the Void – 4:02 Final Warning – 3:54 Cold Chains of the North – 3:39 Wrong Turn – 3:45 Bones and Gasoline – 4:53 Old Habits Die Hard – 3:51 Judgement Day – 4:29 To Hell and Back – 3:34 One More Bullet – 4:06 The Devil's Path – 3:49 Out of Nowhere – 3:26
==== Epitaxy ==== Epitaxial graphene growth on silicon carbide is a wafer-scale technique to produce graphene. Epitaxial graphene may be coupled to surfaces weakly enough (by the active valence electrons that create Van der Waals forces) to retain the two-dimensional electronic band structure of isolated graphene. A normal silicon wafer coated with a layer of germanium (Ge) dipped in dilute hydrofluoric acid strips the naturally forming germanium oxide groups, creating hydrogen-terminated germanium. CVD can coat that with graphene. The direct synthesis of graphene on insulator TiO2 with high-dielectric-constant (high-κ). A two-step CVD process is shown to grow graphene directly on TiO2 crystals or exfoliated TiO2 nanosheets without using any metal catalyst.
low: hs-CRP level under 1.0 mg/L average: between 1.0 and 3.0 mg/L high: above 3.0 mg/L Normal levels increase with aging. Higher levels are found in late pregnant women, mild inflammation and viral infections (10–40 mg/L), active inflammation, bacterial infection (40–200 mg/L), severe bacterial infections and burns (>200 mg/L). CRP cut-off levels indicating bacterial from non-bacterial illness can vary due to co-morbidities such as malaria, HIV and malnutrition and the stage of disease presentation. In patients presenting to the emergency department with suspected sepsis, a CRP/albumin ratio of less than 32 has a negative predictive value of 89% for ruling out sepsis. CRP is a more sensitive and accurate reflection of the acute phase response than the ESR (erythrocyte sedimentation rate). ESR may be normal while CRP is elevated. CRP returns to normal more quickly than ESR in response to therapy.
Sources: en.wikipedia.org
In Germany, phenibut is not approved as a drug and, as a food supplement, is controlled under the German New Psychoactive Substances Act. In a 2023 assessment, the U.S. Food and Drug Administration (FDA) determined that phenibut does not meet the definition of a dietary ingredient, thereby making phenibut supplement products misbranded and illegal for marketing. FDA warning letters had been issued to supplement manufacturers marketing phenibut products as adulterated.
The word Brazil probably comes from the Portuguese word for brazilwood, a tree that once grew plentifully along the Brazilian coast. In Portuguese, brazilwood is called pau-brasil, with the word brasil commonly given the etymology 'red like an ember', formed from brasa ('ember') and the suffix -il (from -iculum or -ilium). It has alternatively been suggested that this is a folk etymology for a word for the plant related to an Arabic or Asian word for a red plant. As brazilwood produces a deep red dye, it was highly valued by the European textile industry and was the earliest commercially exploited product from Brazil. Throughout the 16th century, massive amounts of brazilwood were harvested by indigenous peoples (mostly Tupi) along the Brazilian coast, who sold the timber to European traders in return for assorted European consumer goods. The official Portuguese name of the land, in original Portuguese records, was the 'Land of the Holy Cross' (Terra da Santa Cruz), but European sailors and merchants commonly called it the 'Land of Brazil' (Terra do Brasil) because of the brazilwood trade. Popular usage eclipsed and eventually supplanted the official Portuguese name. Some early sailors called it the 'Land of Parrots'. In the Guarani language, Brazil is called Pindorama, meaning 'land of the palm trees'.
In the US, an increase in gross income will never reduce a taxpayer's post-tax earnings (net income) by putting them in a higher tax bracket. Tax brackets specify marginal tax rates: only income earned in the higher tax bracket is taxed at the higher rate. An increase in gross income can reduce net income in a welfare trap, however, when benefits are withdrawn when passing a certain income threshold. Prevalence of the misconception varies by political party affiliation. Constructing new housing decreases the cost of rent and the price of homes in both the immediate neighborhood and in the city as a whole. In real estate economics, "supply skepticism" leads many Americans to misunderstand the effect of increasing the supply of housing on housing costs. The misconception is unique to the housing market. Businesses do not get a tax benefit by collecting charitable donations from their customers. Corporation taxes are based on profit; the customer's donation would not change the amount of profit and therefore the tax payable. A business would need to donate its own money to receive a tax break. Import tariffs are taxes paid to the government by importers, not by exporting countries or manufacturers as is claimed by some, including Donald Trump. There is a near-unanimous consensus among economists that tariffs have a net-negative effect on economic growth and welfare, and harm consumers through higher prices by more than they benefit domestic producers and governments.
Deslorelin, sold under the brand name Suprelorin among others, is an injectable gonadotropin releasing hormone superagonist (GnRH agonist) which is used in veterinary medicine for various indications.
At the very end of the 19th century, the Japanese administration started the forced assimilation of the native Ainu people. Also at this time the Ainu were granted automatic Japanese citizenship. Many Japanese moved onto former Ainu lands, including the Kuril islands. The Ainu were required to adopt Japanese names. Although not compulsory, education was conducted in Japanese. Prior to Japanese colonization (in 1868) about 100 Ainu reportedly lived on the Kuril islands.
Sources: en.wikipedia.org
== History == Plans for a successor to the original Source engine began following the release of Half-Life 2: Episode Two in 2007. The first engine tech demo was created in 2010 by remaking a map from Left 4 Dead 2. Images of this were leaked onto the internet in early 2014. At the 2014 Game Developers Conference, Valve employee Sergiy Migdalskiy showed off a Source 2 physics debugging tool being used in Left 4 Dead 2. Source 2 was first made available via Steam Workshop tools for Dota 2 in 2014 prior to it being officially announced at the 2015 Game Developers Conference. There, Valve stated their intent for it was to allow for content to be created more efficiently. Valve also stated that it would support the Vulkan graphics API and use a new in-house physics engine called Rubikon, which would replace the need for the third-party Havok tools. Gabe Newell, president and founder of Valve, said that the company were prioritizing the development of their own games before they would release the engine and its software development kit to the public. This was to ensure the highest quality for developers; he added that they were intending to make the engine free to use for game developers as long as the game is published on their Steam service. In June 2015, Valve announced that the entirety of Dota 2 would be ported over to Source 2 in an update called Dota 2 Reborn. Reborn was first released to the public as an opt-in beta update that same month before officially replacing the original client in September 2015, making it the first game to use the engine.
=== Production of ethylene glycol === Ethylene glycol is industrially produced by non-catalytic hydration of ethylene oxide at a temperature of 200 °C (392 °F) and a pressure of 1.5–2 MPa (220–290 psi):
PfSSM (2008), CBM and CCF (2008) for Plasmodium proteins, which have a different amino acid evolutionary bias due to the low GC content of the genome. Matrices for transmembrane proteins. JTT transmembrane (1994) is the first of the class. Later work include: For alpha-helical transmembrane proteins, PHAT (2000) and SLIM (2001). For beta-barrel transmembrane proteins, bbTM (2008). Matrices for a specific protein family, including GPCRtm (2015) for the transmembrane (mostly helical) regions of GPCRs. Matrices for proteins with a specific role, including Hubsm (2017) for "hub proteins" in protein‐protein interaction networks. Matrices for intrinsically disordered proteins, including DUNMat (2002), MidicMat (2009), Disorder (2010), and EDSSMat (2019).
=== 2013 === On 6 January 2013, the NHK announced that Super Hi-Vision satellite broadcasts could begin in Japan in 2016. On January 7, 2013, Eutelsat announced the first dedicated 4K Ultra HD channel. Ateme uplinks the H.264/MPEG-4 AVC channel to the Eutelsat 10A satellite. The 4K Ultra HD channel has a frame rate of 50 fps and is encoded at 40 Mbit/s. The channel started transmission on January 8, 2013. On the same day Qualcomm CEO Paul Jacobs announced that mobile devices capable of playing and recording 4K Ultra HD video would be released in 2013 using the Snapdragon 800 chip. On January 8, 2013, Broadcom announced the BCM7445, an Ultra HD decoding chip capable of decoding High Efficiency Video Coding (HEVC) at up to 4096 × 2160 at 60 fps. The BCM7445 is a 28 nm ARM architecture chip capable of 21,000 Dhrystone MIPS with volume production estimated for the middle of 2014. On the same day THX announced the "THX 4K Certification" program for Ultra HD displays. The certification involves up to 600 tests and the goal of the program is so that "content viewed on a THX Certified Ultra HD display meets the most exacting video standards achievable in a consumer television today". On January 14, 2013, Blu-ray Disc Association president Andy Parsons stated that a task force created three months ago is studying an extension to the Blu-ray Disc specification that would add support for 4K Ultra HD video. On January 25, 2013, the BBC announced that the BBC Natural History Unit would produce Survival—the first wildlife TV series recorded in 4K resolution.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.